Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2021  |  Volume : 17  |  Issue : 74  |  Page : 373-378

Efficacy and safety on Moringa oleifera on blood glucose and lipid profile: A meta-analysis

1 Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand
2 Pharmaceutical Chemistry and Natural Products Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand
3 Department of Pharmacy, Somdej Hospital, Somdej Kalasin, Thailand

Correspondence Address:
Wiraphol Phimarn
Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham 44150
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pm.pm_49_20

Rights and Permissions

Background: Results from previous clinical trials in which the effects of Moringa oleifera (MO) on blood glucose and lipid profile were investigated are controversial. Objectives: The main objective of this study was to assess the effects of MO consumption on blood glucose level and lipid profile in randomized controlled trial (RCTs) and non-RCTs. Materials and Methods: A comprehensive systematic review was performed by searching the PubMed, ScienceDirect, Scopus, and Thai Library Integrated System databases up to December 2019 without any language restrictions by two independent authors. The DerSimonian and Laird random-effects model method was used to pool the results. Results: Seven trials with 257 participants and treatment duration of 28–90 days were included. The pooled results showed a significant reduction in fasting blood sugar (FBS; weighted mean difference [WMD]: −14.81 mg/dL; 95% confidence interval [CI]: −27.99, −1.63; I2 = 97.8%), postprandial glucose (PPG) (WMD − 64.73 mg/dL; 95% CI: −102.87, −26.59; I2 = 93%) and no significant change in HbA1C (WMD: 0.70%; 95% CI: −1.42, 0.69; I2 = 99%), low-density lipoprotein (WMD − 11.20 mg/dL; 95% CI: −34.12, 11.72; I2 = 8.08%), total cholesterol (WMD − 4.73 mg/dL; 95% CI: −24.96, 15.49; I2 = 80%), and triglycerides (WMD − 3.29 mg/dL; 95% CI: −9.95, 3.36; I2 = 29%). Moreover, MO treatment increased high-density lipoprotein (HDL) level significantly (WMD 2.15 mg/dL; 95% CI: 1.92, 2.39; I2 = 0%). No serious adverse effects of the intervention were reported. Conclusion: The results of our study suggested that MO treatment decreased FBS, PPG levels and increase HDL level. However, the long-term benefits and safety of the treatment remain to be determined.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded220    
    Comments [Add]    

Recommend this journal